

**REMARKS/ARGUMENTS**

The Substitute Specification merely includes typographical or clerical changes and does not include new matter. Support for these amendments may be found throughout the specification, claims or drawings, as filed. In particular, the amendment to paragraph [0046] clarifies that the references cell population is a "normal" cell population. Support for this amendment may be found, for example, in paragraph [0055]. The amendment to paragraph [0081] merely corrects a grammatical error and is obvious when read in the context of the preceding sentence. The amendment to paragraph [0108] corrects an oversight in the original specification. Support for this amendment may be found for example, in claims 38 through 42, as filed. The amendments to paragraphs [0148] and [0151] delete reference to an under-expressed gene and polypeptide. Support for these amendments may be found, for example, in paragraph [0015]. No new matter is added.

A Sequence Listing on paper and in computer readable form was prepared in accordance with 37 C.F.R. §§1.821 to 1.825, and is submitted herewith. The Sequence Listing does not include new matter or matter that goes beyond the disclosure of the International Application.

The information contained in the computer readable disk was prepared through the use of the software program "FastSeq" and is identical to that of the paper copy of the Sequence Listing.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Kevin Eastman  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
Attachments  
KLB:ath  
60854727 v1